Every SEC Form 3/4/5 on record for this filer (CIK 1827015) — 4 issuers, 6 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | Director | 2022-08-02 → 2026-06-15 | 8 | −$132,300 |
| ZYME | Zymeworks Inc. | Director | 2024-02-09 → 2026-01-12 | 4 | — |
| SMMT | Summit Therapeutics Inc. | Director | 2022-11-17 → 2026-01-06 | 6 | — |
| EPIX | ESSA Pharma Inc. | Chief Medical Officer · lapsed | 2020-10-01 → 2024-03-28 | 4 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| PBYI | 2025-07-18 | Sell | 27,000 | $3.37 | $90,990 | 41,850 |
| PBYI | 2025-06-13 | Sell | 12,150 | $3.40 | $41,310 | 68,850 |
3 of 4 issuers are covered and open a security page; the rest are on file here only.